TICKERNERD
Menu
CYRXCYRXIndustrials · Integrated Freight & Logistics

CYRX Stock Forecast: Cryoport, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$17
−5.47% on the day

The 9 Wall Street analysts covering Cryoport, Inc. hold a median 12-month price target of $20 — +15.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 31 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$926.4M
Ticker Nerd rank
73/ 100
Median analyst target
$20
Analysts covering
9
Revenue$49.0M+7.7% y/y
Operating income−$10.0M
Net income−$8.3M
Free cash flow−$8.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−0.6%
YTD
+80.1%
1Y
+92.1%
From 52W high
−7.2%
From 52W low
+124.0%
$8
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CYRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cryoport, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
73/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Accruals
78
Quality
76
Revisions
56
Value
55
Volatility
50
Issuance
46
Size
45
Growth
40

Momentum (96): The shares have been drifting up relative to others.

Growth (40): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CYRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26CYRXHigh $26Median $20Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $15Median $20High $26

The green dot is the last close — the median target sits +15.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026BTIGMaintainsBuy$25 → $26
1 Oct 2026GuggenheimMaintainsBuy$16 → $19
1 Oct 2026GuggenheimMaintainsBuy—
18 Sept 2026BTIGReiteratesBuy$25
18 Sept 2026BTIGReiteratesBuy—
7 Aug 2026GuggenheimMaintainsBuy$12 → $16
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026NeedhamMaintainsBuy$15 → $19
7 Aug 2026NeedhamMaintainsBuy—
24 July 2026BTIGMaintainsBuy$17 → $25
24 July 2026BTIGMaintainsBuy—
3 June 2026Craig-HallumMaintainsBuy—
3 June 2026Craig-HallumMaintainsBuy$15 → $20
20 May 2026KeybancMaintainsOverweight—
5 May 2026BTIGMaintainsBuy—
5 May 2026GuggenheimMaintainsBuy—
5 May 2026NeedhamMaintainsBuy—
30 Mar 2026Craig-HallumInitiatesBuy—
4 Mar 2026NeedhamMaintainsBuy—
5 Nov 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CYRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CYRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Cryoport, Inc. returned +92.1% against +12.4% for the S&P 500, dividends included.

CYRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26CYRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CYRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Cryoport, Inc. (CYRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.3×

Cheaper than 52% of US stocks

Price / sales
4.7×

Cheaper than 24% of US stocks

Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
−233.7×

Cheaper than 98% of US stocks

Growth & margins
Revenue growth (YoY)
7.7%

Higher than 47% of US stocks

Earnings growth (YoY)
7.7%

Higher than 46% of US stocks

Gross margin
46.6%

Higher than 58% of US stocks

Operating margin
−20.4%

Higher than 21% of US stocks

Net margin
−20.1%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−6.5%

Higher than 38% of US stocks

Return on assets
−2.4%

Higher than 36% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cryoport, Inc. (CYRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cryoport, Inc. has a market value of $926.4M and an enterprise value of $808.0M.

  • Revenue in the twelve months to 30 June 2026: $186.5M. The latest quarter grew 7.7% year on year.

  • Net income over the same four quarters: −$37.4M, a −20.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.90.

  • Free cash flow in the twelve months to 30 June 2026: −$21.3M.

  • Shares outstanding: 50.6M.

  • Trailing P/E: 12.3×; forward P/E: −26.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cryoport, Inc. employs 684 people — $273K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

CYRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelIntegrated Freight & Logistics
CompanyMarket capTKN rank
CYRXCryoport, Inc.$926.4M73
FWRDForward Air Corp.$595.2M70
RLGTRadiant Logistics, Inc.$425.7M98
PBIPitney Bowes, Inc.$2.2B98
SERVServe Robotics, Inc.$225.4M4
LSTRLandstar System, Inc.$4.9B72
GXOGXO Logistics, Inc.$5.8B60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cryoport, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CYRX news & analysis

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells

Seeking Alpha · 30 Oct 2026neutral

The Seeking Alpha excerpt says Conestoga remained encouraged by the operational performance of micro-cap companies in its portfolios. It highlights TWST's share surge after strong fiscal third-quarter results and TKNO's higher full-year revenue outlook; it provides no specific update on Cryoport.

Why it matters — The excerpt offers no direct Cryoport-specific information, so it has limited relevance to CYRX watchers.

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?

Zacks Investment Research · 1 Oct 2026neutral

The article compares the year-to-date performance of CryoPort, Inc. (CYRX) with that of Delcath Systems, Inc. (DCTH) relative to their medical sector. It focuses on how both companies have fared against their sector benchmark so far this year.

Why it matters — A CYRX watcher would want to know how the stock's year-to-date returns stack up against its medical-sector peers.

Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals

Seeking Alpha · 25 Sept 2026positive

Seeking Alpha reports on Cryoport's strong cell and gene therapy commercialization and pipeline momentum, noting the company returned to adjusted EBITDA profitability in 2Q26 with positive operating cash flow of $8 million TTM. Management expects five new CGT commercial approvals in 2026, supported by a 15% year-over-year increase in the Phase 3 trial pipeline to 94 trials.

Why it matters — The reported return to profitability, strong operating cash flow, and expected new commercial approvals and growing Phase 3 pipeline signal expanding growth drivers for Cryoport's core cell and gene therapy business.

CryoPort (CYRX) Upgraded to Buy: Here's Why

Zacks Investment Research · 11 Aug 2026positive

CryoPort (CYRX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects, according to Zacks Investment Research.

Why it matters — The upgrade signals improved analyst sentiment around CryoPort's earnings outlook, which CYRX watchers would take note of.

FAQ

Frequently asked questions about CYRX stock

What is the CYRX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Cryoport, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYRX stock a buy right now?

Of the 9 analysts covering Cryoport, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cryoport, Inc. 73 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYRX?

As at 31 Oct 2026, Cryoport, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will CYRX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +15.7% from the last close, and Ticker Nerd's factor model ranks Cryoport, Inc. 73 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYRX stock forecast for 2030?

No analyst covering Cryoport, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $26 over the next 12 months.

How has CYRX stock performed over the past year?

Cryoport, Inc. returned +92.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cryoport, Inc. do?

Cryoport Inc. is a global life sciences logistics and services company focused on temperature-controlled supply chain solutions for biologic materials.

What is the latest news on CYRX?

The most recent item we track (Seeking Alpha, 30 Oct 2026): "Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells". The Seeking Alpha excerpt says Conestoga remained encouraged by the operational performance of micro-cap companies in its portfolios. It highlights TWST's share surge after strong fiscal third-quarter results and TKNO's higher full-year revenue outlook; it provides no specific update on Cryoport.

Company

About Cryoport, Inc.

Cryoport Inc. is a global life sciences logistics and services company focused on temperature-controlled supply chain solutions for biologic materials. Cryoport Inc. supports the movement, storage, handling, and monitoring of sensitive products used in cell and gene therapy, biopharmaceuticals, animal health, and reproductive medicine. Its current offerings include specialized bio-logistics, bio-storage, bio-processing, cryopreservation, and cryogenic equipment, along with related software and monitoring tools designed to help maintain product integrity throughout transit and storage. Through its Life Sciences Services and Life Sciences Products segments, Cryoport Inc. serves biotechnology and pharmaceutical companies, contract research organizations, fertility clinics, and other healthcare-focused customers worldwide. Headquartered in Brentwood, Tennessee, Cryoport Inc. plays an important role in the infrastructure that supports advanced therapies and other temperature-sensitive life sciences applications.

CEO Mr. Jerrell W. Shelton · 684 employees · United States · https://www.cryoportinc.com